NKGN NKGen Biotech, Inc.: institutional ownership and insider trading
1 funds reported holding $165K of NKGen Biotech, Inc. in their latest 13F filings; in Q2 2026 funds net bought $0, with 0 new positions and 0 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
NKGN revenue and earnings
- Quarter ended Mar 31, 2025: revenue n/a, net income $15.4M, EPS -0.04
- Quarter ended Dec 31, 2024: revenue n/a, net income −$29.4M, EPS -0.77
- Quarter ended Sep 30, 2024: revenue n/a, net income $6.60M, EPS 0.15
- Quarter ended Jun 30, 2024: revenue n/a, net income −$16.1M, EPS -0.67
Largest institutional holders of NKGN
- METEORA CAPITAL, LLC — $165K
Recent NKGN insider trades
- May 27, 2025: Cherng Peggy bought 19,669,552 shares ($2.56M)
- May 5, 2025: Song Paul Y. bought 20,849,725 shares ($2.71M)
5%+ owners
- Paul Y. Song: 54.3% (Schedule 13D, filed May 12, 2025)
- CFIC-2015 NV Family Investments, LLC: 47.2% (Schedule 13D, filed Jun 2, 2025)
- PATHSTONE FAMILY OFFICE, LLC: 7.9% (Schedule 13G, filed Feb 28, 2025)
- Meteora Capital, LLC: 6.1% (Schedule 13G/A, filed May 15, 2025)
Who owns the most NKGN stock?
The largest institutional holders of NKGen Biotech, Inc. in the latest 13F filings are METEORA CAPITAL, LLC ($165K).
Are insiders buying or selling NKGN?
No open-market insider buys or sells of NKGen Biotech, Inc. were reported in the last 12 months.